Diabetes & Metabolic Syndrome-Clinical Research & Reviews最新文献

{"title":"Differential associations between smoking, e-cigarette use, and diabetes prevalence","authors":"Yusuff Adebayo Adebisi ,&nbsp;Chimwemwe Ngoma ,&nbsp;Davide Campagna ,&nbsp;Antonio Ceriello ,&nbsp;Najim Z. Alshahrani ,&nbsp;Anoop Misra ,&nbsp;Abdul Basit ,&nbsp;Cristina Russo ,&nbsp;Tadej Battelino ,&nbsp;Noel Somasundaram ,&nbsp;Muhammad Yazid Jalaludin ,&nbsp;Phuong Le Dinh ,&nbsp;Yoshifumi Saisho ,&nbsp;Magdalena Walicka ,&nbsp;Venera Tomaselli ,&nbsp;Giulio Cantone ,&nbsp;Othmar Moser ,&nbsp;Riccardo Polosa","doi":"10.1016/j.dsx.2025.103331","DOIUrl":"10.1016/j.dsx.2025.103331","url":null,"abstract":"<div><h3>Background</h3><div>Cigarette smoking is a well-established risk factor for diabetes, but the relationship between e-cigarette use and diabetes remains uncertain. Evidence to date has been drawn almost entirely from North America and Asia, with little information from European populations.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional study of 17,854 adults aged 16 years and older from the 2017, 2018, 2019, and 2021 waves of the nationally representative Scottish Health Survey. Diabetes status was based on self-report of doctor-diagnosed diabetes. Participants were classified into six mutually exclusive categories of smoking and e-cigarette use: never users of either cigarettes or e-cigarettes, ex-smokers (former smokers who never used e-cigarettes), current exclusive cigarette smokers, current exclusive e-cigarette users, current dual users, and former e-cigarette users. Weighted prevalence estimates and survey-weighted binary logistic regression models were used to examine associations, adjusting for age group, sex, education, deprivation quintile, ethnicity, alcohol use, physical activity, and hypertension.</div></div><div><h3>Results</h3><div>Diabetes prevalence was highest among ex-smokers (11.3 %, 95 % CI: 10.1–12.5). Prevalence was 5.7 % (95 % CI: 5.2–6.2) among never users of either cigarettes or e-cigarettes, 6.2 % (95 % CI: 4.9–7.9) among current exclusive cigarette smokers, 4.9 % (95 % CI: 3.4–7.1) among current exclusive e-cigarette users, 8.3 % (95 % CI: 5.8–11.8) among current dual users, and 5.1 % (95 % CI: 4.1–6.3) among former e-cigarette users. In adjusted models, ex-smokers had 35 % higher odds of diabetes compared with never users of either cigarettes or e-cigarettes (OR = 1.35, 95 % CI = 1.14–1.60, p &lt; 0.001), whereas current exclusive smokers (OR = 0.78, 95 % CI = 0.58–1.03, p = 0.084), current exclusive e-cigarette users (OR = 0.81, 95 % CI = 0.53–1.22, p = 0.309), current dual users (OR = 1.49, 95 % CI = 0.94–2.38, p = 0.091), and former e-cigarette users (OR = 1.00, 95 % CI = 0.78–1.29, p = 0.973) were not significantly different from never users. Sensitivity analyses restricting ex-smokers to those with ≥5 years since cessation and limiting the sample to adults aged ≥45 years reproduced the same pattern of results.</div></div><div><h3>Conclusions</h3><div>In this nationally representative study of Scottish adults, excess diabetes prevalence was observed among ex-smokers, a pattern that may reflect both reverse causation if individuals quit smoking after diagnosis and the lasting metabolic effects of cumulative smoking exposure. Neither current nor former e-cigarette use was associated with diabetes, and the observed variation in prevalence appeared linked to smoking history rather than e-cigarette use. However, because vaping is relatively recent, further longitudinal research is needed to clarify any long-term risks.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 10","pages":"Article 103331"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145624734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artichoke and cardiometabolic health: A systematic and meta-analytic synthesis of current evidence","authors":"Ali Jafari ,&nbsp;Mohammad Amin Karimi ,&nbsp;Mahsa Mahmoudinezhad ,&nbsp;Fatemeh Razavi ,&nbsp;Helia Mardani ,&nbsp;Vali Musazadeh","doi":"10.1016/j.dsx.2025.103328","DOIUrl":"10.1016/j.dsx.2025.103328","url":null,"abstract":"<div><h3>Background and aims</h3><div>This systematic review and meta-analysis was conducted to evaluate the effects of artichoke supplementation on cardiometabolic health markers in adults.</div></div><div><h3>Methods</h3><div>A comprehensive literature search of PubMed, Scopus, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials was conducted up to September 2024.</div></div><div><h3>Results</h3><div>Artichoke supplementation significantly reduced body mass index (WMD = −0.51 kg/m², 95 % CI: 0.93 to −0.09) and waist circumference (WMD = −1.21 cm, 95 % CI: 2.24 to −0.17), while its effects on body weight and hip circumference were not statistically significant. Blood pressure outcomes revealed significant reductions in both systolic (WMD = −2.49 mmHg, 95 % CI: 4.33 to −0.65) and diastolic (WMD = −1.53 mmHg, 95 % CI: 3.01 to −0.05) pressures. Significant lipid profile improvements were observed in total cholesterol (WMD = −12.29 mg/dL, 95 % CI: 19.92 to −4.65), low-density lipoprotein cholesterol (WMD = −10.31 mg/dL, 95 % CI: 18.57 to −2.04), and triglycerides (WMD = −12.85 mg/dL, 95 % CI: 24.77 to −0.93), with no significant effect on high-density lipoprotein cholesterol. Regarding glycemic indices, insulin (WMD = −1.83 mU/L, 95 % CI: 3.33 to −0.32) and homeostatic model assessment for insulin resistance (WMD = −0.92, 95 % CI: 1.33 to −0.51) were significantly reduced, whereas fasting blood glucose and HbA1c were unaffected. Among liver function markers, alanine aminotransferase (WMD = −8.47 U/L, 95 % CI: 14.71 to −2.23) and alkaline phosphatase (WMD = −7.86 U/L, 95 % CI: 15.26 to −0.45) were significantly reduced, while aspartate aminotransferase showed a borderline non-significant effect. No significant change was observed in creatinine levels.</div></div><div><h3>Conclusion</h3><div>Artichoke supplementation may offer modest but significant improvements in several cardiometabolic risk markers.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 10","pages":"Article 103328"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145575120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From 1990 to 2021, the burden of diabetes among the elderly in the Western Pacific Region (WPR) and projections for 2040 prevalence: A systematic analysis of the 2021 Global Burden of Disease study","authors":"Yve Han ,&nbsp;Huaxing Lou ,&nbsp;Peng Zhao ,&nbsp;Hui Li ,&nbsp;Congyi Zhang ,&nbsp;Hongru Sun","doi":"10.1016/j.dsx.2025.103324","DOIUrl":"10.1016/j.dsx.2025.103324","url":null,"abstract":"<div><h3>Aims</h3><div>The study aims to quantify the changes in the age-standardized prevalence of Type 1 and type 2 diabetes among the elderly in the Western Pacific Region (WPR) from 1990 to 2021.</div></div><div><h3>Methods</h3><div>We analyzed data on diabetes prevalence, mortality, and DALYs among the elderly from the GBD, stratified by sex, age, and SDI. We calculated ASR, used APC and AAPC to assess trends, and conducted correlation, decomposition, and health inequality analyses.</div></div><div><h3>Results</h3><div>From 1990 to 2021, the age-standardized prevalence of type 1 and type 2 diabetes increased in the region's elderly. In 2021, rates were 19,573.81 per 100,000 for type 2 and 191.98 per 100,000 for type 1. Men experienced a higher burden, and type 2's burden increased with age. A negative SDI-diabetes burden correlation was observed, highlighting socio-economic complexities.</div></div><div><h3>Conclusion</h3><div>The rising trends in diabetes prevalence and DALYs among the elderly in the Western Pacific Region underscore the growing challenge of managing diabetes in an aging society. This highlights the need for targeted interventions and policies to address the health impacts of diabetes on the elderly population.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 10","pages":"Article 103324"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145558898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experience with insulin detemir for type 2 diabetes in older people and people with comorbidities","authors":"Melanie J. Davies ,&nbsp;Amra Ciric Alibegovic ,&nbsp;Anders Boeck Jensen ,&nbsp;Renuka Munikrishnappa ,&nbsp;Uffe Christian Braae","doi":"10.1016/j.dsx.2025.103327","DOIUrl":"10.1016/j.dsx.2025.103327","url":null,"abstract":"<div><h3>Aims</h3><div>This real-world study assessed glycemic levels and further clinical outcomes, following initiation of detemir, in sub populations of people with T2D vulnerable to hypoglycemia.</div></div><div><h3>Methods</h3><div>This retrospective cohort study included people registered in the United Kingdom Clinical Practice Research Datalink (CPRD) GOLD database who initiated detemir between January 2004 and December 2019. Analyses were stratified by age, previous insulin experience, and history of renal, liver or cardiovascular disease (CVD).</div></div><div><h3>Results</h3><div>In total, 8975 eligible study participants were identified (44.4 %, aged ≥65 years; 23.7 %, renal disease; 15.6 %, CVD; 2.2 %, liver disease; 53.3 %, insulin-naïve). Six months post-index estimated changes (95 % confidence intervals [CI]) in HbA1c and body weight were −1.00 % (−1.1; −0.9) (−11 mmol/mol [−12; −9]) and 0.35 kg (0.03; 0.66), respectively. Rates of hypoglycemia were low, with no increase between pre- and post-index periods. Compared with pre-index, the mean number of oral glucose-lowering therapy prescriptions per person and mean number of people receiving each type of glucose-lowering therapy decreased post-index.</div></div><div><h3>Conclusions</h3><div>Detemir appears to be an effective and well-tolerated treatment for T2D in older people, and those with CVD, renal disease or liver disease.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 10","pages":"Article 103327"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145624735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of body roundness index with stroke and mortality among people with normal body mass index","authors":"Yuan Shen ,&nbsp;Ruobing Tian ,&nbsp;Xue Xia ,&nbsp;Shuohua Chen ,&nbsp;Xue Tian ,&nbsp;Shouling Wu ,&nbsp;Anxin Wang","doi":"10.1016/j.dsx.2025.103313","DOIUrl":"10.1016/j.dsx.2025.103313","url":null,"abstract":"<div><h3>Objectives</h3><div>The Body Roundness Index (BRI) is a novel anthropometric measure that can predict total and regional body fat percentages. However, the effects of BRI in individuals with a normal Body Mass Index (BMI) remain unclear. This study aimed to investigate the association of BRI with stroke and all-cause mortality in individuals with a normal BMI.</div></div><div><h3>Methods</h3><div>This longitudinal study included 36,490 participants free from cardiovascular diseases (CVD) and possessed a normal BMI (18.5–24.0) at baseline. Cox proportional hazard models were used to estimate the associations between BRI and the risk of stroke and all-cause mortality. Receiver operating characteristic (ROC) curves were used to assess the ability of BRI to predict stroke and all-cause mortality than other anthropometric indices.</div></div><div><h3>Results</h3><div>During a median follow-up of 15.0 years, there were 2281 (6.3 %) recorded strokes and 5094 (14.0 %) deaths. After adjusting for potential risk factors, BRI was found to be significantly associated with increased risks of stroke (<em>P</em> for trend = 0.002) and mortality (<em>P</em> for trend &lt;0.001), independent of BMI. The association was primarily linked to ischemic stroke (<em>P</em> for trend = 0.002) rather than hemorrhagic stroke. Additionally, the ROC curves indicated that BRI has better predictive power than BMI for stroke and all-cause mortality (<em>P</em> &lt; 0.05).</div></div><div><h3>Conclusion</h3><div>In participants with a normal BMI, higher levels of BRI were significantly associated with an increased risk of stroke and all-cause mortality. However, these findings may not generalize to women or more diverse populations, as the study mostly included men from a single occupation.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 9","pages":"Article 103313"},"PeriodicalIF":3.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145365410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highlights of the current issue","authors":"Ningjian Wang ,&nbsp;Anoop Misra","doi":"10.1016/j.dsx.2025.103317","DOIUrl":"10.1016/j.dsx.2025.103317","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 9","pages":"Article 103317"},"PeriodicalIF":3.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145624059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interventions for prediabetes: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials","authors":"Nicola Veronese ,&nbsp;Stefania Maggi ,&nbsp;Cristina Giussani ,&nbsp;Matteo Bianchini ,&nbsp;Hend Alfadul ,&nbsp;Shaun Sabico ,&nbsp;Nasser Al-Daghri ,&nbsp;Lee Smith ,&nbsp;Damiano Pizzol ,&nbsp;Federica Limongi ,&nbsp;Jacopo Demurtas ,&nbsp;Alessandra Bartolini ,&nbsp;Michela Zanetti","doi":"10.1016/j.dsx.2025.103303","DOIUrl":"10.1016/j.dsx.2025.103303","url":null,"abstract":"<div><h3>Aims</h3><div>This umbrella review synthesized evidence from systematic reviews and meta-analyses of randomized controlled trials (RCTs) to assess the effectiveness of interventions for preventing adverse outcomes in individuals with prediabetes.</div></div><div><h3>Methods</h3><div>A total of 23 meta-analyses comprising 602 RCTs and over 30,000 participants were analyzed from databases including Medline, Embase, Web of Science, and Cochrane through February 1, 2025. Interventions evaluated included both pharmacological and non-pharmacological strategies compared to placebo or usual care. Studies reporting only bio-humoral markers were excluded. The GRADE approach was used to assess the certainty of evidence.</div></div><div><h3>Results</h3><div>Among 15 evaluated interventions, four were supported by high-certainty evidence for diabetes prevention: GLP-1 receptor agonists (RR = 0.26), liraglutide/exenatide/semaglutide (OR = 0.29), orlistat (OR = 0.67), and structured self-care programs (OR = 0.58). High-certainty evidence also supported modest reductions in systolic blood pressure (∼2–3 mmHg) from lifestyle interventions, digital health tools, and liraglutide. Significant reductions in BMI and waist circumference were observed with pharmacologic agents, aerobic exercise, and digital platforms. However, metformin combined with lifestyle changes did not yield notable anthropometric benefits.</div></div><div><h3>Conclusion</h3><div>These findings underscore the value of a multidimensional and personalized approach to prediabetes management, emphasizing evidence-based pharmacological options alongside behavioral and digital health strategies.</div></div><div><h3>Systematic review registration</h3><div>PROSPERO CRD42025649619.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 9","pages":"Article 103303"},"PeriodicalIF":3.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145395694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A randomized pilot sleep and circadian behavior clinical trial to improve glycemic and psychological outcomes in young adults with type 1 diabetes (NCT04975230)","authors":"Bethany L. Armentrout ,&nbsp;Megan L. Wenzell ,&nbsp;Kingman P. Strohl ,&nbsp;Sybil L. Crawford ,&nbsp;Jamie R. Wood ,&nbsp;Chiang-shan R. Li ,&nbsp;Ronald L. Hickman Jr. ,&nbsp;Stephanie Alisha Griggs","doi":"10.1016/j.dsx.2025.103305","DOIUrl":"10.1016/j.dsx.2025.103305","url":null,"abstract":"<div><h3>Aims</h3><div>To investigate the preliminary efficacy of a cognitive behavioral sleep and circadian intervention on glycemic and psychological outcomes in young adults with type 1 diabetes.</div></div><div><h3>Methods</h3><div>Glycemic and psychological outcomes were evaluated in 39 young adults (mean age 21.08, diabetes duration 11.7 years, mean glycated hemoglobin 8.46 %, 41 % female) from March 2022 to October 2023. Participants were randomly assigned (1:1) to a 12-week cognitive behavioral sleep and circadian condition (n = 21) or a time-balanced attention control condition (n = 18). Data were collected using continuous glucose monitors, research-grade actigraphy, and daily sleep surveys at baseline, post-intervention, and 3-month follow-up.</div></div><div><h3>Results</h3><div>The cognitive behavioral sleep and circadian intervention condition showed significant improvements in glycemic outcomes, with reductions in the coefficient of variation and mean amplitude of glucose excursions three months post-intervention. It also resulted in decreased diabetes distress at both time points, unlike the Attention Control group, which had minimal changes.</div></div><div><h3>Conclusions</h3><div>Future research should confirm these preliminary findings in larger, more diverse samples with varied intervention lengths and a longer-term follow-up.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 9","pages":"Article 103305"},"PeriodicalIF":3.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145331424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The economic impact of diabetes: Assessing incremental direct costs in Australia using linked administrative data","authors":"Bernard Kwadwo Yeboah Asiamah-Asare ,&nbsp;Sean Randall ,&nbsp;George Mnatzaganian ,&nbsp;Richard Varhol ,&nbsp;Crystal Man Ying Lee ,&nbsp;Kevin Chai ,&nbsp;James Boyd ,&nbsp;Gill Cowen ,&nbsp;Sangita Shakya ,&nbsp;Lan Gao ,&nbsp;Suzanne Robinson","doi":"10.1016/j.dsx.2025.103302","DOIUrl":"10.1016/j.dsx.2025.103302","url":null,"abstract":"<div><h3>Background</h3><div>Diabetes poses huge financial implications for individuals and healthcare systems. This study aims to quantify the incremental direct healthcare costs associated with diabetes in Australia.</div></div><div><h3>Methods</h3><div>This matched retrospective cohort study used a linked administrative dataset for Western Australia. Diabetes cases (n = 18,937) were matched 1:1 to controls based on age, sex, remoteness, and weight status. Direct healthcare costs incurred by the government, including costs of hospital admissions, emergency presentations, prescribed medications, general practice visits, and pathology tests, were estimated for 2021, with costs expressed in 2024 Australian Dollars (AUD). The incremental cost was calculated as the difference between the average annual costs of people with diabetes and those without diabetes, and the cost was extrapolated to the total population in 2024.</div></div><div><h3>Results</h3><div>Average annual healthcare costs per person with diabetes (AUD 9677) were 2.1 times higher than those without diabetes (AUD 4669). The average annual costs attributable to people with Type 2 Diabetes (AUD 5135) were higher than those with Type 1 Diabetes (AUD 4295). The incremental costs of diabetes (AUD 5008) significantly varied across age groups, remoteness, weight status, socioeconomic status and smoking status. In Australia, the total healthcare cost associated with diabetes in 2024 was estimated at AUD 14.2 billion, and the total incremental cost associated with diabetes was estimated at AUD 7.3 billion.</div></div><div><h3>Conclusions</h3><div>Diabetes imposes a substantial excess direct healthcare cost burden. Evidence could guide the planning and allocation of resources, as well as support the need for targeted health interventions.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 9","pages":"Article 103302"},"PeriodicalIF":3.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145351288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Compounded incretins in clinical practice: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy","authors":"Lindsay A. Courtney ,&nbsp;Jennifer N. Clements ,&nbsp;Diana Isaacs ,&nbsp;Jamie M. Pitlick ,&nbsp;Sara Mandy Reece ,&nbsp;Heather P. Whitley","doi":"10.1016/j.dsx.2025.103314","DOIUrl":"10.1016/j.dsx.2025.103314","url":null,"abstract":"<div><h3>Aims</h3><div>This article aims to summarize the role of compounded incretin mimetics in clinical practice and in the context of drug shortages.</div></div><div><h3>Methods</h3><div>The Endocrine and Metabolism Practice and Research Network, a focused group of the American College of Clinical Pharmacy members, convened an independent committee to evaluate the role of compounded incretin mimetics.</div></div><div><h3>Results</h3><div>There is limited data demonstrating positive clinical outcomes in small cohorts of patients receiving compounded semaglutide and tirzepatide. However, there remain significant legal and safety concerns since compounded incretins do not undergo approval by the Food and Drug Administration.</div></div><div><h3>Conclusion</h3><div>Whenever possible, healthcare providers should make every effort to assist patients with obtaining approved medications. If patients choose to obtain compounded incretins, providers can encourage safety by ensuring use of reputable compounding pharmacies and routinely monitoring patients for safety and efficacy of the compounded product.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 9","pages":"Article 103314"},"PeriodicalIF":3.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145424978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}